News & Updates
Showing Obstetrics & Gynaecology articles
Showing
Show Multimedia Only

Prexasertib works in select patients with recurrent ovarian cancer
14 Oct 2022
CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.
14 Oct 2022

Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer
12 Oct 2022
byAudrey Abella
In the second interim overall survival (OS) analysis of the phase III TROPiCS-02 study, sacituzumab govitecan (SG) – a first-in-class Trop-2*-directed antibody-drug conjugate approved for triple-negative metastatic breast cancer (mBC) with ≥2 prior therapies (≥1 in the metastatic setting) – conferred an OS benefit for pretreated HR+/HER2– mBC, compared with treatment of physician’s choice (TPC**).
12 Oct 2022






